PROGRAMME

SATELLITE SYMPOSIA

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:30 – 16:00 Sheikh Rashid E

Novo Nordisk

Advances in metabolic science and therapies

08:30 **Pre-symposium breakfast**

The effects of GLP-1 on satiety and metabolism

09:00 **Welcome and introduction**
Chair: Ken Fujioka (US)

09:10 **Obesity and prediabetes: a disease continuum**
Nick Finer (UK)

09:30 **Does GLP-1 play a role in satiety in normal physiology?**
Niels Vrang (DK)

09:50 **Gastric bypass and GLP-1**
Ken Fujioka (US)

10:05 **GLP-1 and weight loss: emerging science**
Arne Astrup (DK)

10:30 **Panel discussion**
All faculty

10:45 **Coffee break**

Incretins in diabetes: from pathophysiology to therapeutic use

11:15 **Welcome and introduction**
Chair: Melanie Davies (UK)

11:25 **New insights into the pathophysiology of incretin regulation**
Filip Knop (DK)

11:50 **What next, when metformin fails?**
Richard Pratley (US)

12.20 **Further intensification: present and future**
Stephen Gough (UK)

12:45 **Insight into guidelines: an interactive discussion**
Melanie Davies (UK), Bernard Zinman (CA)

12:55 **Introduction to designing better therapy**
Bernard Zinman (CA)

13:00 **Lunch**

Steps towards future insulin therapy – how far have we come?

14:00 **Welcome and introduction**
Chair: Bernard Zinman (CA)

14:15 **The idea – multi-hexamer soluble**
Peter Kurtzhals (DK)

14:40 **The action – pharmacological profiles**
Thomas Pieber (OS)

15:00 **The start – clinical data on basal only therapy**
Chantal Mathieu (BE)

15:15 **The next step – clinical data on basal–bolus therapy**
Miles Fisher (UK)

15:40 **Closing remarks**
Bernard Zinman (CA)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

08:00 – 10:00 Sheikh Maktoum B

Colgate-Palmolive

Diabetes and oral health

Chair: Eva Kan

08.00 **Introduction**
Eva Kan, Alice Ho Miu Ling Nethersole Hospital, Hong Kong

08.05 **The diabetes- oral health (periodontal disease) relationship: patho-physiology and epidemiology**
Speaker: To be announced

08.35 **Incorporating oral health into team care for diabetes prevention and lifelong management**
Betsy Rodriguez, Centers for Disease Control and Prevention, Atlanta, United States

09.05 **IDF oral health resources for diabetes care providers:**
- **IDF Guideline: Oral health for people with diabetes**
- **IDF Diabetes Education Module: Oral health**

Martin Gillis, Dalhousie University, Halifax, Canada

09.35 **Interactive Q & A between speakers and audience**

This symposium is supported by an educational grant from Colgate-Palmolive.

11:00 – 13:00 Sheikh Maktoum B

Pronokal

The current impact of obesity and clinical evidence supporting the protein diet as a tool for the medical management of excess weight.

11:00 **Obesity and Diabetisty worldwide**
Dr. Felipe Casanueva

11:30 **Prokal Research Study: results up to one year**
Dr. Basilio Moreno

12:00 **Diaprokal Research Study: preliminary results**
Dr. Albert Goday

12:30 **Presentation of the Diaprokal Method**
Dra. Ana Bellon

14:00 – 16:00 Sheikh Maktoum D

Sanofi

Recent Developments in GLP-1 Based Therapy for People with Type 2 Diabetes Mellitus

Chair: J. Leahy

14:00 **Welcome and Introduction**
J. Leahy

14:05 **GLP-1 agonists in the Diabetes Landscape**
J. Meier

14:35 **Emerging Data from the GetGoal Program**
D. Raccah

15:05 **Complementing Basal Insulin: Combining Existing and New Therapeutic Pathways**
L. Van Gaal

15:35 **Discussion and Q&A**
All

15:50 **Conclusions**
J. Leahy

14.00 – 16.00 Sheikh Maktoum A

Bristol-Myers Squibb/AstraZeneca

Cut the burden: Break through diabetes

Chair: Dr. Ghaida Kaddaha, M.R.C.P., F.R.C.P. (Dubai)

14:00 **Welcome & Introduction**
Dr. Ghaida Kaddaha, M.R.C.P., F.R.C.P. (Dubai)

14:15 **Facing the hurdles in type 2 diabetes management**
Ian Blumer, M.D., F.R.C.P.C. (Canada)

14:40 **DPP4-inhibition: Taking diabetes management to a new level**
Dr. Ghaida Kaddaha, M.R.C.P., F.R.C.P. (Dubai)

15:05 **Saxagliptin: A DPP4-inhibitor in action**
Robert Henry, M.D. (U.S.A.)

15:30 **Question and Answer**

15:50 **Closing and Evaluation**
Dr. Ghaida Kaddaha, M.R.C.P., F.R.C.P. (Dubai)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

14:00 – 16:00 Sheikh Maktoum B

Bayer Schering Pharma

Postprandial hyperglycaemia and T2DM: managing cause and effect

Chair: A Ceriello ES, N Tajima JP

14:00 **Welcome & introduction**
N Tajima, JP

14:05 **Postprandial hyperglycaemia: What's new?**
A Ceriello, ES

14:20 **Postprandial hyperglycaemia: How to manage the starting point of diabetes**
N Tajima, JP

14:40 **Strategy for newly diagnosed T2DM patients: An update**
W Yang, CN

15:00 **SMBG for better management of diabetes**
O Schnell, DE

15:15 **Obesity and T2DM: is testosterone a therapeutic option for men?**
F Saad, DE

15:35 **Interindividual variability in response to low-dose Aspirin**
C Patrono, IT

15:50 **Summary & closing remarks**
A Ceriello, ES

13:00 – 14:00 Industry forum

Bayer HealthCare Diabetes Care

Innovations for Diabetes Management: Looking Toward the Future

13:00 **Introduction: Technology Advances Based on Patient Need**
Tim Bailey, MD
As advances in technology are developed, it is necessary to have the technology adopted and used in order to improve glucose management.

13:10 **Data Management and Patient Empowerment: What's the Evidence?**
Peter Swartz, MD
Findings from a large trial examining the use of diabetes management software and the design of a new trial to determine whether the use of easy-to-use software can help guide patient self-care will be discussed.

13:30 **Innovations in SMBG**
Tim Bailey, MD
Introduction of a new innovation from Bayer – an easy to use meter that addresses the new proposed accuracy standards and advancing technology requirements to assist patients in improving their diabetes management will be previewed.

13:50 **Summary and Q and A**

18:00 – 20:00 Sheikh Rashid E

Lilly Diabetes

Diabetes Management during Ramadan in the Muslim World

Chair: Dr Fatheya Al Awadi

18:00 **Opening remarks**
Dr Fatheya Al Awadi

18:10 **What are the risks of fasting and benefit of focused education for people with diabetes?**
Dr Mohamed Hassanein

18:35 **Q&A**

18:45 **How should patients with diabetes who fast for Ramadan be managed?**
Prof. Khalifa Mahmoud Abdallah, MD

19:10 **Q&A**

19:20 **CREED: results of an observational study on the management and outcomes of patients with diabetes during Ramadan**
Dr Salem Beshyah

19:45 **Q&A**

19:55 **Closing remarks**
Dr Fathya Al Awadi

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

18:00 – 20:00 Al Multaqua Ballroom

Merck Serono

Improving Health Outcomes in 2011 for patients with Type 2 Diabetes

Chair: Prof P. Home, Newcastle - UK
Chair: Prof M. Almaatouq, Riyadh - Saoudi Arabia

Disease burden in the Middle East - facing up to the epidemic of type 2 Diabetes
Prof M Almaatouq, Riyadh, KSA

Worldwide policies aimed at primary and secondary prevention
Prof P Home, Newcastle, UK

The role of B vitamins in diabetic complications
Prof Carl-Heinz Reiners, Hamburg,Germany

Vitamin B status in diabetic patients
Dr Rima Obeid, Saarlandes, Germany

Life saving benefits of metformin - reducing cardiovascular and cancer deaths
Prof J Chan, Hong Kong

18:00 – 20:00 Sheikh Maktoum A

Abbott

Going beyond current standards of care in patients with type 2 Diabetes

Type 2 Diabetes treatment, have we reached the limit?
Paul Zimmet, Australia

The place of fibrates in the treatment of type 2 diabetic patients
Jiten Vora, UK

Risk-benefit ratio of fibrate and statin combination: are all fibrates equal?
Malik Rayaz, UK

18:00 – 20:00 Sheikh Maktoum B

Merck Sharp & Dohme

The evolution of DPP-4 inhibition in type 2 Diabetes

Chair: Hussain Saadi (United Arab Emirates)

18:00 **Welcome and Introduction**
Hussain Saadi (United Arab Emirates)

18:05 **Can Intervention Change The Course of Beta Cell Function?**
Steven Kahn (United States)

18:30 **Q&A**

18:40 **The Expanding Role of Sitagliptin in Diabetes Management: New Clinical Data**
Michael Nauck (Germany)

19:10 **Q&A**

19:20 **Combination Therapy: Aligning Treatment Goals with Therapeutic Options**
John Prins (Australia)

19:45 **Q&A**

19:55 **Closing Remarks**
Hussain Saadi (United Arab Emirates)

18:00 – 20:00 Sheikh Maktoum C

Novo Nordisk

Navigating the route to good glycaemic control

Chair: Robert Ligthelm

18:00 **Welcome and introduction**
Robert Ligthelm

18:05 **Exploring the evidence behind the updated IDF guidelines**
Stephen Colagiuri

18:30 **The journey to better glycaemic control: the importance of PGR**
Antonio Ceriello

18:55 **Finding the path from initiation to intensification**
Robert Ligthelm

19:20 **Panel discussion**
All

19:50 **Summary and close**
Robert Ligthelm

18:00 – 20:00 Sheikh Maktoum D

Sanofi

The Impact of Socio-Economic Determinants: Can We Do Better for People with Diabetes in Emerging Countries?

Chairs: G. Bolli
Chairs: L. Ji

18:00 **Welcome and Introduction**
Chairs

18:05 **The Reality of Diabetes in Emerging Countries**
K. Al Jaberi

18:35 **How does the Cultural and Socio-Economic Context Impact the Management of Type 2 Diabetes**
F.J. Lavalle-Gonzalez
A. Ramachandran

19:05 **Caring for People with Type 1 Diabetes**
J. Skyler

19:30 **Partnerships for Improving Type 1 Diabetes in China: The 3-C Study**
L. Ji
J.C. Mbanya
R. Perfetti

19:50 **Conclusions**
Chairs

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

10:00 – 11:00 Industry Forum

Becton, Dickinson and Company (BD)

Improving the Diabetes Injection Experience through Science and Innovation

Principle Challenges in Diabetic Injection
Dr. Anders FRID

Possible Solutions to the Principle Challenges
Dr. Ken STRAUSS

Ultrasound practical illustrating challenges and solutions
Drs. STRAUSS with audience participation

Questions and Answers
Drs. FRID and STRAUSS

18:00 – 20:00 Sheikh Maktoum B

Institute of Diabetes Research Group

State-of-the-(HE)ART-symposium: CVD risk prediction and management

Chair: M. Hanefeld, A. Ceriello

A symposium of the Diabetes Research Group at the Helmholtz Center Munich and the Diabetes & Cardiovascular Disease EASD Study Group

18:00 **Estimating individual CVD risk in Type 2 diabetes**
R. Holman

18:20 **Self-monitoring of blood glucose: Impact on CV risk in diabetes**
O. Schnell

18:40 **Patterns of continuous glucose monitoring: A role for prediction or cardiac arrhythmias?**
M. Hanefeld

19:00 **Statin and RAAS inhibitor for every diabetic patient?**
E. Standl

19:20 **Diabetes in Asia: Strategies for CVD prevention**
L. Ji

19:40 **The need for individualized medicine in diabetes**
A. Ceriello

18:00 – 20:00 Al Multaqua Ballroom

Lilly Diabetes

GLP-1 Therapy in Type 2 Diabetes: Recent Advances and Controversy

18:00 **Opening remarks**
Bernard Zinman, Canada

18:10 **Regulation of GLP-1 production and secretion: new emerging concepts**
Piero Marchetti, Italy

18:30 **Q&A**

18:35 **Which should be used to intensify after oral antihyperglycemic therapy**

a. Basal insulin
Guntram Schernthaner, Austria

b. GLP-1 receptor agonist
Michael Nauck, Germany

19:15 **Q&A**

19:25 **New insights in GLP-1 receptor based therapy**
Michaela Diamant, Netherlands

19:45 **Q&A**

19:55 **Closing remarks**
Bernard Zinman, Canada

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

18:00 – 20:00 Sheikh Maktoum A

Umeå University Hospital

A CME accredited educational programme organised by Umeå University Hospital on the occasion of the World Diabetes Congress, 2011.

This programme is supported by an unrestricted educational grant from Bristol-Myers Squibb and AstraZeneca

SGLT2 inhibition – a new therapeutic approach to the management of type 2 diabetes mellitus (T2DM)

Course Director: Prof. Tommy Olsson, Umeå, Sweden
Chair: Prof. Clifford Bailey, Birmingham, UK
Chair: Prof. Ele Ferrannini, Pisa, Italy

18:00 **The need to treat glucotoxicity**
Ele Ferrannini, University of Pisa, Italy

18:30 **SGLT2 inhibition: new concept, new reality?**
Clifford Bailey, Aston University, UK

19:00 **SGLT2 inhibitors across the T2DM spectrum: earlier disease**
Krzysztof Strojek, Silesian Medical University, Poland

19:30 **SGLT2 inhibitors across the T2DM spectrum: later disease**
John Wilding, University Hospital Aintree, UK

This educational programme is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) for up to 2 hours of European external CME credits. Each participant should claim only those hours of credit that have actually been spent in the educational activity.The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

This programme is supported by an unrestricted educational grant from Bristol-Myers Squibb and AstraZeneca

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

18:00 – 20:00 Sheikh Maktoum C

Boehringer Ingelheim GmbH

New Directions in Type 2 Diabetes

Co-chairmen: Steven Kahn, Baptist Gallwitz

18:00 **Chairman's introduction**
Baptist Gallwitz

18:05 **Type 2 diabetes: the Middle Eastern perspective**
Hussein Saadi

18:20 **Challenges in type 2 diabetes management**
Steven Kahn

18:40 **DPP-4 inhibitors: raising expectations**
Vivian Fonseca

19:00 **Exploring the role for DPP-4 inhibitors**
Baptist Gallwitz

19:25 **Is the kidney the ignored heart of type 2 diabetes?**
Mark Cooper

19:45 **Panel discussion**
Faculty

19:55 **Meeting summary and close**
Steven Kahn

18:00 – 20:00 Sheikh Maktoum D

Servier

Treatment of type 2 diabetes: a matter of proof

Chair: D. Matthews (UK)
Chair: M. Marre (France)

Introduction
D. Matthews (UK)

Optimal management of type 2 diabetes: the evidence
S. Colagiuri (Australia)

Treating diabetes today: a matter of selectivity
S. Seino (Japan)

Treating diabetes today with Gliclazide MR: a matter of number
S. Hadjadj (France)

What matters in ADVANCE and ADVANCE-ON
P. Hamet (Canada)

Conclusion
M. Marre (France)

08:00 09:00 10:00 11:00 12:00 13:00 14:00 15:00 16:00 17:00 18:00 19:00 20:00 21:00 22:00

18:00 – 20:00 Sheikh Rashid F

ISPAD

Internists and pediatricians working together to improve the care of children and adolescents with diabetes in developing countries

Chairs: Ragnar Hanas and Johnny Ludvigsson

18.00 **Introduction**
Johnny Ludvigsson, Linköping University, Sweden

18.05 **The evolvement of childhood diabetes care – a long journey from internal medicine to pediatrics; The South American experience**
Gloria Lopez, First University Chile, Santiago, Chile

18.25 **How can internists and pediatricians make this transition smoothly in Africa?**

Experiences from the Changing Diabetes® in Children programme - Ethiopia
Ahmed Reja, Black Lion Hospital, Addis Ababa, Ethiopia
Bereket Fantahun, Black Lion Hospital, Addis Ababa, Ethiopia

Experiences from the IDF Life for a Child programme - Nigeria
Abiola Oduwole, University of Lagos, Nigeria
Afokoghene Rita Isiavwe, University of Lagos, Nigeria

19.05 **Capacity building in developing countries; The ISPAD experience**
Stuart Brink, NEDEC, Waltham MA and Tufts University School of Medicine, Boston MA, USA

19.25 **Interactive Q&A between speakers and the audience.**

This ISPAD Symposium is supported by an unrestricted grant from the Changing Diabetes® in Children programme and Novo Nordisk.